AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer

Too Little, Too Late In Crowded Market

 
• By Andrew McConaghie
Astrazeneca
AstraZeneca is the market leader in EGFR-positive lung cancer, but trails far behind Merck and BMS in the PD-1/PD-L1 market.

More from Business

More from Scrip